Computer-guided dosing of multi-specific T-cell engagers
5 affiliations
- 1Department of Biomedical Engineering, University of Utah, Salt Lake City, UT USA
- 2Huntsman Cancer Institute, University of Utah, Salt Lake City, UT USA
- 3Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT USA
- 4U2TAH Therapeutics Accelerator, University of Utah, Salt Lake City, UT USA
- 5Department of Statistics, Brigham Young University, Provo, UT USA
Abstract
Patient-specific tumor heterogeneity limits the efficacy of conventional T-cell immunotherapies. We report MATCH, a modular split-antibody T-cell engager platform, and COMPASS, a computational framework that predicts individualized multi-specific therapy compositions. COMPASS integrates T-cell counts, tumor burden, and antigen expression (CD19, CD20, CD38) to identify dose combinations that maximize tumor cell killing while preserving T-cell viability. COMPASS accurately predicted effective multi-specific formulations for chronic lymphocytic leukemia patient PBMC samples and successfully predicted compositions to treat a human lymphoma xenograft murine model that led to significantly improved survival. This lab-in-the-loop experimental-computational approach provides a generalizable blueprint for precision T-cell immunotherapy and offers a new paradigm in patient-specific cancer treatment.
Related
- Incidence of Acute Kidney Injury in the Model-Based AUC-Guided Dosing of Vancomycin Compared with Conventional Trough-Guided Dosing in Patients with Severely Impaired Renal Function
- Electronic-Nomogram-Guided Micafungin Dosing Regimen in Critically Ill Patients: A Population Pharmacokinetic Study
- Renal Function–Guided Valganciclovir Dosing and Ganciclovir Exposure Variability: A Population Pharmacokinetic Simulation Study
- Muscle- and Gland-Specific Dosing of Botulinum Toxin in Facial Aesthetics: Review of Dose Ranges, Target Depth, Muscle Thickness, and Neuromuscular or Glandular Anatomy.
- Genotype-guided isoniazid dosing harmonizes drug exposure in 3HP tuberculosis preventive therapy
BibTeX
@article{kendell2026computerguided,
title = {{Computer-guided dosing of multi-specific T-cell engagers}},
author = {Isaac Kendell and Richard McShinsky and Katarzyna Modzelewska and Lauren Naatz and Alex Stark and David Bearss and Jeffry Troll and Douglas Sborov and Shawn Owen and M. Tommy Gambles},
journal = {Communications Biology},
year = {2026},
month = jul,
doi = {10.1038/s42003-026-10602-4},
url = {https://doi.org/10.1038/s42003-026-10602-4},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Computer-guided dosing of multi-specific T-cell engagers
AU - Isaac Kendell
AU - Richard McShinsky
AU - Katarzyna Modzelewska
AU - Lauren Naatz
AU - Alex Stark
AU - David Bearss
AU - Jeffry Troll
AU - Douglas Sborov
AU - Shawn Owen
AU - M. Tommy Gambles
PY - 2026
DA - 2026/07/13
JO - Communications Biology
DO - 10.1038/s42003-026-10602-4
UR - https://doi.org/10.1038/s42003-026-10602-4
AB - Patient-specific tumor heterogeneity limits the efficacy of conventional T-cell immunotherapies. We report MATCH, a modular split-antibody T-cell engager platform, and COMPASS, a computational framework that predicts individualized multi-specific therapy compositions. COMPASS integrates T-cell counts, tumor burden, and antigen expression (CD19, CD20, CD38) to identify dose combinations that maximize tumor cell killing while preserving T-cell viability. COMPASS accurately predicted effective multi-specific formulations for chronic lymphocytic leukemia patient PBMC samples and successfully predicted compositions to treat a human lymphoma xenograft murine model that led to significantly improved survival. This lab-in-the-loop experimental-computational approach provides a generalizable blueprint for precision T-cell immunotherapy and offers a new paradigm in patient-specific cancer treatment.
SN - 2399-3642
ER -